GlassScriptPhysician profile
Gisela Velez
NPI 1639119167
$7,703.65
in general payments reported to CMS, 2019-2025
22 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $2,095 · 2021: $379 · 2022: $834 · 2023: $1,034 · 2024: $1,258 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,385.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,456.98 | 2019-2022 | |
| Abbvie INC. | $1,648.70 | 2019-2025 | Durysta, Ozurdex |
| Genentech USA, INC. | $677.35 | 2019-2025 | Vabysmo |
| Alcon Vision LLC | $405.52 | 2022-2025 | Rocklatan, Hydrus Microstent, Eysuvis |
| Astellas Pharma US INC | $323.66 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $305.68 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $299.38 | 2021-2023 | Acthar |
| Tarsus Pharmaceuticals, INC. | $287.68 | 2024-2025 | Xdemvy |
| Coherus Oncology, INC. | $212.55 | 2023-2024 | |
| Biogen, INC. | $185.05 | 2023-2024 | Byooviz |
| Thea Pharma INC. | $148.17 | 2023-2024 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $123.34 | 2019-2025 | |
| Sandoz INC. | $115.92 | 2024-2025 | Cimerli |
| Dompe US, INC. | $106.55 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $76.04 | 2022-2024 | Tyrvaya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $69.63 | 2023-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $61.35 | 2019-2020 | |
| Horizon Therapeutics Plc | $57.42 | 2022-2023 | Tepezza |
| Apellis Pharmaceuticals, INC. | $49.05 | 2022-2024 | Syfovre |
| Bausch & Lomb Americas INC. | $42.01 | 2022-2024 | Miebo |
| Sight Sciences, INC. | $38.24 | 2023-2024 | Tearcare System |
| Mallinckrodt Enterprises LLC | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gisela Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.